Abstract:

This review article discusses the FINE-HEART pooled analysis, which has investigated the efficacy and safety of finerenone in patients with heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes (T2D). Finerenone is a non-steroidal MRA, which delivers marked value in reducing cardiovascular mortality, hospitalization due to heart failure, and the progression of kidney disease, especially in patients with overlapping cardiovascular-kidney-metabolic (CKM) conditions. Several trial results, including FIDELIO-DKD and FIGARO-DKD, were combined to provide an overall overview of the treatment outcomes. The following review discusses the study design, key results, and clinical implications of finerenone use in high-risk populations and concludes that finerenone presents substantial benefits in the management of patients with CKD, HF, and T2D while maintaining an acceptable safety profile.

References:

[1].   Vaduganathan, M., Filippatos, G., Claggett, B. L., et al., 2024, Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nature Medicine. https://doi.org/10.1038/s41591-024-03264-4.

[2].   Ostrominski, J. W., et al., 2024, Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis. Journal of the American College of Cardiology, 84, 223–228.

[3].   Ndumele, C. E., et al., 2023, Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation, 148, 1606–1635.

[4].   Bakris, G. L., et al., 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England Journal of Medicine, 383, 2219–2229.

[5].   Agarwal, R., et al., 2022, Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European Heart Journal, 43, 474–484.

[6].   Neuen, B. L., et al., 2024, Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation, 149, 450–462.